BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces FY2020 Business, Financial Results

April 19, 2021 12:03:02

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has released its 2020 financial results and has filed its annual report for the fiscal year ended Dec. 31, 2020. Company highlights include bringing the production of NeuroCaps(TM) to the United States; launching the commercial roll-out of its NeuroEEG(TM) and NeuroCap(TM) on a limited basis in the United States market; establishing wholly owned subsidiaries in Russia and Poland; and a significant increase in research and development efforts. Furthermore, the company announced that it has filed a provisional patent application for a new long-term monitoring EEG cap; in addition, its proprietary NeuroCap is now available in the U.S. pediatric market. Financial highlights include reported revenue of $544,275 for fiscal year 2020, compared to $489,202 for fiscal year 2019 with total company assets at the end of 2020 reaching $440,218 compared to $291,002 at the end of 2019. “In 2020, Brain Scientific made good progress toward our vision of introducing transformative brain diagnostic solutions that apply cutting-edge technologies and establish a new innovative norm for clinicians,” said Brain Scientific board chair Boris Goldstein in the press release. “We made strides on the operations front to improve lead times and quality control, as well as connections to expand our customer base in early 2021.”

To view the full press release, visit

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork